eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium Georges Rawadi appointed eureKARE's Chief of Biotech Studio Development Luxembourg, Belgium
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson's Disease - Data from the company's CHELATE trial to be presented today during an oral presentation
Investegate announcements from Orphalan, Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease
Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia - 4BIO Capital